Ruohui Chen

Dr. Ruohui Chen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
SHSheri J Hartman
Sheri J Hartman
RCRuohui Chen
Ruohui Chen
RTRowena M Tam
Rowena M Tam
HNHari K Narayan
Hari K Narayan
LNLoki Natarajan
Loki Natarajan
LLLin Liu
Lin Liu
Background: There has been a rapid increase in the use of commercially available activity trackers, such as Fitbit, in physical activity intervention research. However, little is known about the long-term sustained use of trackers and behavior change after short-term interventions. Objective: This study aims to use minute-level data collected from a Fitbit tracker for up to 2 years after the end of a randomized controlled trial to examine patterns of Fitbit use and activity over time. Methods: Participants in this secondary data analysis were 75 female breast cancer survivors who had been enrolled in a 12-week physical activity randomized controlled trial. Participants randomized to the exercise intervention (full intervention arm) received a Fitbit One, which was worn daily throughout the 12-week intervention, and then were followed for 2 years after the intervention. Participants randomized to the waitlist arm, after completing the randomized controlled trial, received a Fitbit One and a minimal version of the exercise intervention (light intervention arm), and then were followed for 2 years after the intervention. Average and daily adherence and MVPA were compared between the 2 groups in the interventional and postinterventional periods using both linear and generalized additive mixed effects models. Results: Adherence to wearing the Fitbit during the 12-week intervention period was significantly higher in the full intervention arm than in the light intervention arm (85% vs 60%; P<.001). Average adherence was significantly lower for both study arms during the follow-up period than in the intervention period; however, there were statistically different patterns of adherence during the follow-up period, with the light intervention arm having steeper declines than the full intervention arm over time (P<.001). Similar to the adherence results, mean minutes of Fitbit-measured MVPA was higher for the full intervention arm than for the light intervention arm during the 12-week intervention period (mean MVPA 27.89 minutes/day, SD 16.38 minutes/day vs 18.35 minutes/day, SD 12.64 minutes/day; P<.001). During the follow-up period, average MVPA was significantly lower than the 12-week intervention period for both the full intervention arm (21.74 minutes/day, SD 24.65 minutes/day; P=.002) and the light intervention arm (15.03 minutes/day, SD 13.27 minutes/day; P=.004). Although the mean MVPA in each arm was similar across the follow-up period (P=.33), the pattern of daily MVPA was significantly different between the 2 groups (P<.001). Conclusions: While adherence to wearing activity trackers and maintaining physical activities declined after completion of a 12-week exercise intervention, a more active interventional strategy resulted in greater wear time and activity levels during the intervention and more stable patterns of adherence and activity in the long term. An improved understanding of long-term maintenance patterns may inform improved exercise interventions that result in sustained increases in physical activity. Trial Registration: ClinicalTrials.gov NCT02332876; https://clinicaltrials.gov/ct2/show/NCT02332876

15 May 2024 in Journal of Applied Statistics
Verified
Journal Article
Closed access
RCRuohui Chen
Ruohui Chen
TLTuo Lin
Tuo Lin
LLLin Liu
Lin Liu
JLJinyuan Liu
Jinyuan Liu
RCRuifeng Chen
Ruifeng Chen
XTXin Tu
Xin Tu
The Mann-Whitney-Wilcoxon rank sum test (MWWRST) is a widely used method for comparing two treatment groups in randomized control trials, particularly when dealing with highly skewed data. However, when applied to observational study data, the MWWRST often yields invalid results for causal inference. To address this limitation, Wu et al. (Causal inference for Mann-Whitney-Wilcoxon rank sum and other nonparametric statistics, Stat. Med. 33 (2014), pp. 1261-1271) introduced an approach that incorporates inverse probability weighting (IPW) into this rank-based statistic to mitigate confounding effects. Subsequently, Mao (On causal estimation using U-statistics, Biometrika 105 (2018), pp. 215-220), Zhang et al. (Estimating Mann Whitney-type causal effects, J. Causal Inference 7 (2019), ARTICLE ID 20180010), and Ai et al. (A Mann-Whitney test of distributional effects in a multivalued treatment, J. Stat. Plan. Inference 209 (2020), pp. 85-100) extended this IPW estimator to develop doubly robust estimators. Nevertheless, each of these approaches has notable limitations. Mao's method imposes stringent assumptions that may not align with real-world study data. Zhang et al.'s (Estimating Mann Whitney-type causal effects, J. Causal Inference 7 (2019), ARTICLE ID 20180010) estimators rely on bootstrap inference, which suffers from computational inefficiency and lacks known asymptotic properties. Meanwhile, Ai et al. (A Mann-Whitney test of distributional effects in a multivalued treatment, J. Stat. Plan. Inference 209 (2020), pp. 85-100) primarily focus on testing the null hypothesis of equal distributions between two groups, which is a more stringent assumption that may not be well-suited to the primary practical application of MWWRST. In this paper, we aim to address these limitations by leveraging functional response models (FRM) to develop doubly robust estimators. We demonstrate the performance of our proposed approach using both simulated and real study data.

26 August 2025 in Circulation
Verified
Journal Article
Closed access
SHSheri J. Hartman
Sheri J. Hartman
ALAndrea Z. LaCroix
Andrea Z. LaCroix
Dorothy D SearsDorothy D Sears
Dorothy D Sears
LNLoki Natarajan
Loki Natarajan
RZRong W. Zablocki
Rong W. Zablocki
DRDori Rosenberg
Dori Rosenberg
BACKGROUND: Public health and clinical guidelines identify the importance of sedentary behaviors for cardiovascular diseases, particularly among postmenopausal women. The goal of this trial was to compare the behavioral and physiological impacts of 2 distinct approaches to changing sedentary behaviors. METHODS: Overweight or obese sedentary postmenopausal women (N=407) were randomly assigned to 1 of 3 study conditions for 3 months: (1) healthy living (control), (2) reduce sitting time (sit less), and (3) increase sit-to-stand transitions (STSTs; sit-to-stand). Each study arm received 7 individual health coach sessions across 12 weeks. At baseline and 3 months, participants had fasting blood drawn, had blood pressure measured, and wore thigh (activPAL) and hip (ActiGraph) accelerometers for 7 days. Linear mixed models evaluated each intervention arm compared with the control (healthy living) arm. RESULTS: A total of 388 women (95%) completed the 3-month trial. The sit less arm reduced total sitting time by 58 minutes per day more than the healthy living arm (95% CI, –82.9 to –33.6; P <0.001) but did not change STSTs (–1 STST/day [95% CI, –9.4 to 6.5]; P =0.72). Conversely, the sit-to-stand arm significantly increased STST by 26 STST per day more than the healthy living arm (95% CI, 17.71 to 33.64; P <0.001) but did not differ in change to sitting time (–10 min/day [95% CI, –34.6 to 14.9]; P =0.44). The sit-to-stand arm had significant decreases in diastolic blood pressure compared with the healthy living arm (–2.24 mm Hg [95% CI, –4.08 to –0.40]; P =0.02) and similar decreases in systolic blood pressure compared with the healthy living arm (–3.33 mm Hg [95% CI, –6.32 to –0.33]; P =0.03), although it did not reach the a priori significance threshold of P <0.025. There were no significant intervention effects on blood pressure for the sit less arm and no intervention effects for the glucoregulatory outcomes for either arm. CONCLUSIONS: This trial demonstrated the feasibility of changing sedentary behaviors as well as the distinct nature of sitting time and STST. Increasing STST improved blood pressure in overweight and obese postmenopausal women within 3 months. Focusing on increasing STST may be an achievable behavioral target to reduce cardiovascular disease risk in postmenopausal women. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03473145.

27 March 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
RKReem Karmali
Reem Karmali
CGCarlos Galvez
Carlos Galvez
MHMehdi Hamadani
Mehdi Hamadani
LGLeo Gordon
Leo Gordon
JWJane Winter
Jane Winter
BPBarbara Pro
Barbara Pro
MYC-aberrant non-Hodgkin lymphoma (NHL) is associated with poor outcomes with conventional chemotherapy. Ixazomib is an orally bioavailable proteasome inhibitor that targets drivers of MYC expression and has demonstrated preclinical activity in aggressive MYC-aberrant NHL. We conducted a phase 1/2 study evaluating the safety and efficacy of DA-EPOCH-R with adjunctive ixazomib in aggressive MYC-aberrant NHL. For induction, patients received 6 cycles of DA-EPOCH-R with ixazomib administered twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year. Primary objectives were to determine the maximum tolerated dose in phase 1 and efficacy of DA-EPOCH-R with ixazomib as measured by 12-month progression-free survival (PFS) rate in phase 2. Thirty-six patients were evaluable for response. Median age was 63 years (range, 31-77) and 44% had double-hit lymphoma (DHL)/triple-hit lymphoma (THL). In phase 1, 3 mg of ixazomib was established as recommended phase 2 dose. Twenty-nine (76.3%) patients completed 6 cycles of DA-EPOCH-R and 25 (65.8%) underwent dose escalations. The ORR after induction was 97% (95% confidence interval, 81-100) with a CR rate of 69%. At median follow-up of 18.8 months, the 12-month PFS and overall survival (OS) rates were 78% and 86%, respectively. For DHL/THL vs dual expressor lymphomas (DEL), 12-month PFS rates were 53% vs 95% and 12-month OS rates were 65% vs 100%, respectively. Grade ≥3 toxicities were predominantly hematologic. Twenty-seven (75%) of patients experienced neuropathy, nearly all low-grade. DA-EPOCH-R induction with adjunctive ixazomib is feasible and appears effective in patients with DEL. This trial was registered at www.clinicaltrials.gov as #NCT02481310.

31 May 2025 in Annals of Epidemiology
Verified
Journal Article
Closed access
DFDavid Jun Fei-Zhang
David Jun Fei-Zhang
EGErik B. Gerlach
Erik B. Gerlach
SCShyam Chandrasekar
Shyam Chandrasekar
MPMark A. Plantz
Mark A. Plantz
NANicholas C. Arpey
Nicholas C. Arpey
TPTerrance D. Peabody
Terrance D. Peabody

27 November 2025 in International Journal of Cancer
Verified
Journal Article
Open access
AHAtieh A Hajirahimkhan
Atieh A Hajirahimkhan
EBElizabeth T. Bartom
Elizabeth T. Bartom
CCCarolina Chung
Carolina Chung
XGXingyu Guo
Xingyu Guo
Kyli BerkleyKyli Berkley
Kyli Berkley
Seema Ahsan KhanSeema Ahsan Khan
Seema Ahsan Khan
Anti‐estrogens have had a limited impact on breast cancer (BC) prevention. Novel agents with better tolerability, and efficacy beyond estrogen receptor (ER) positive BC are needed. We studied licochalcone A (LicA) for ER‐agnostic BC prevention. We demonstrated that LicA significantly reduced proliferation in seven human breast cell lines and suppressed ER+ and ER− xenograft tumors in mice. We confirmed these observations ex vivo in the contralateral unaffected breast (CUB) of women with unilateral sporadic BC, and BC cell lines using RNA sequencing, metabolism flux modeling, confirmatory NanoString nCounter metabolic pathway panel analysis in independent sets of specimens, proteomics, and western blots. We found that LicA targets sterol regulatory element binding protein 1 (SREBP1) with subsequent metabolic‐inflammatory changes, lowering spatiotemporally resolved cholesterol levels inside malignant cells to the levels in normal mammary cells. Mechanistically, in CUBs we observed that LicA downregulated PI3K‐AKT‐SREBP1‐dependent lipogenesis, NF‐kB‐dependent inflammation, and de novo nucleotide biosynthesis, stalling proliferation. Studies in cell lines showed suppression of PI3K and AKT phosphorylation, SREBP1 protein expression, and the SREBP1‐dependent enzymes such as ACAT2, ACLY, FASN, SCD, consistent with reduced NEDD8 required for SREBP1 stabilization. We found a significant reduction in NF‐kB expression, its nuclear translocation mediator karyopherin β 1, and prostaglandin E2 synthesis. We demonstrated a reduction in PRPS1‐catalyzed de novo nucleotide biosynthesis, and downregulation of proliferative markers MKI67, RRM2, and the survival marker BCL2. LicA reduces pro‐tumorigenic aberrations in lipid homeostasis and inflammation through SREBP1. It is a promising non‐endocrine candidate for BC prevention. Future studies in immunocompetent BC prevention models are warranted.